Licensing deal for Dyax

Dyax Corp., a Cambridge biotechnology company, said today that it has licensed its antibody phage display libraries to a subsidiary of AstraZeneca, the British pharmaceuticals giant.

Financial terms of the agreement were not disclosed.

The AstraZeneca subsidiary is Cambridge Antibody Technology, or CAT, and the licensing agreement allows CAT the ability to commercialize up to 20 royalty-bearing therapeutic antibody products, Dyax said.
(By Chris Reidy, Globe staff)